Lilly Medical US’ Post

Lots of exciting developments in #psoriasis #psoriaticarthritis #lupus to follow. I guess that's why #venturecapital investing $250M+ here. #clinicaltrials #arthritis #medicine #heathcare

Today we presented positive data from a Phase 2 clinical trial of ESK-001, a highly selective allosteric TYK2 inhibitor, for the treatment of plaque #psoriasis at the American Academy of Dermatology Annual Meeting. Learn more: https://lnkd.in/e9pKPCBM #AAD2024

The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment : In this Dermatology Times article, listen to Christopher Bunick, MD, PhD, as he delves into current data and guidelines to consider when creating custom treatment plans for patients with atopic dermatitis. https://lnkd.in/gsDAMw86

Experts in dermatology provide a comprehensive year in review regarding the management of plaque psoriasis, highlighting key therapeutic approvals from 2023. The discussion will highlight pivotal clinical studies supporting these approvals and our discussion will then pivot to have a special focus on addressing the unique challenges faced by treating patients with skin of color and treatment access barriers. Explore the series here: https://ow.ly/az7y50RSCnx

Want to learn more about our AtopicDermatitis registry. Let’s schedule a meeting and discuss how we can support your dermatology development initiatives. #rwe #rwd #registry #atopicdermatitis

We eagerly await the results of this pivotal clinical trial of dupilumab I designed together with dermatology colleagues Pascal Joly, Victoria Werth and Arsalan Shabbir for bullous pemphigoid. Here is the trial rationale and design. https://lnkd.in/gs5tZbcd

I am privileged to share our new article published in the American Journal of Clinical Dermatology, which focuses on the use of topical calcineurin inhibitors on atopic dermatitis patients among the Taiwanese population. Please feel free to discuss and share your comments with me! https://lnkd.in/gYnFpfMh #atopicdermatitis #cohortstudy #topicalcalcineurininhibitors #NationalHealthinsuranceResearchDatabase

How do you integrate new, largely clinically untested, therapeutic technology platforms with deep biological, clinical, regulatory, marketing, and distribution in highly specific diseases? Today, etherna announces ( https://lnkd.in/eHEzbEcn) one approach to this problem by partnering with Almirali, a leader in dermatology in order to usher in a new generation of mRNA drugs for skin diseases. This capitalizes on the synergy between state of the art custom LNP-mRNA capabilities (etherna) and world class knowledge and execution capabilities in an important organ system. Other partnerships are soon to follow. Many technology platform companies are caught between two worlds, having to optimize a clinically unproven technology platform, deliver this optimized platform to partners, and then to identify/execute/fund internal programs towards a specific drug target or disease, often without the depth of biological/clinical/regulatory/marketing know-how in this specific area. As a result, poor choices are made for the internal candidate and the outcome of the platform companies becomes an open question. Such has been the fate of many platform companies currently, and why they are falling out of favor at this moment. This has been the conundrum also for companies moving from mRNA vaccines (where the path is clear) to mRNA therapeutics where there are many options but where POC in the clinic is yet to be fully achieved. Now that I am formally retired from academia ( https://lnkd.in/eekppGWm), I am hoping to use my deep knowledge and biological intuition in the of CV/metabolic/renal diseases to work with partners, including etherna, to enhance the development of a new generation of mRNA drugs. Looking forward to future interactions with my many colleagues in the biotechnology arena going forward.

At the end of #AAD2024, Andrew Alexis, MD, MPH, vice-chair for diversity and inclusion for the department of dermatology and professor of clinical dermatology at Weill Cornell Medicine, discussed the significance of new tapinarof cream findings as they relate to the current state of clinical management of atopic dermatitis skin of color. Alexis additionally talked about what specific clinical and demographic challenges patients of color face in adequately treating chronic skin diseases, and what further steps may his peers take to further improve representation in research and care tailored to skin of color. Read here: https://lnkd.in/e_uCYy4M

📚 Would you like to access the latest dermatology news? 📚 Discover our medical reviews on Ask NAOS Pro 👇 https://lnkd.in/dKjMgYZZ The medical reviews offer privileged access to scientific information from international events dedicated to dermatology 🎉 They are a summary of: • Our symposia held during the latest WCD2027, IMCAS, and European Academy of Dermatology and Venereology • Our e-symposia organized in cooperation with the University of Brescia, dedicated to Onco-Dermatology • Meetings of the European Society for Photodermatology, giving an overview of the main topics presented during the previous World Photodermatology Days. #Atopy #Hyperpigmentation #Oncology #Aging #Photoprotection #Photodermatology